AnaptysBio
ANAB
160 hedge funds and large institutions have $1.13B invested in AnaptysBio in 2024 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 62 increasing their positions, 31 reducing their positions, and 11 closing their positions.
236% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 11
100% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 31
51% more capital invested
Capital invested by funds: $747M → $1.13B (+$380M)
19% more funds holding
Funds holding: 135 → 160 (+25)
2.29% more ownership
Funds ownership: 109.06% → 111.35% (+2.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
23% less call options, than puts
Call options by funds: $28.5M | Put options by funds: $36.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$15M |
| 3 |
BlackRock
New York
|
+$14M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$11.7M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$12.5M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$10.4M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$8.2M |
| 4 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$6.26M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$5.64M |
ANAB Hedge Fund Activity: Q3 2024 in Review
160 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q3 2024, worth a combined $1.13B — up 51% from $747M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new ANAB positions and 11 closed out — a net gain of 26 holders — while 62 added to existing stakes and 31 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $21.3M. The largest seller was Camber Capital Management, exiting entirely with an estimated $12.5M sold.
- 160 institutional investors held AnaptysBio (ANAB) as of Q3 2024, up from 135 in Q2 2024.
- Funds reported $1.13B of AnaptysBio stock for Q3 2024, up 51% quarter-over-quarter.
- 37 funds opened new AnaptysBio positions in Q3 2024 and 11 closed out, a net change of +26 holders.
- The largest AnaptysBio buyer in Q3 2024 was T. Rowe Price Associates, an estimated $21.3M added.
- The largest AnaptysBio seller in Q3 2024 was Camber Capital Management, an estimated $12.5M sold.
Based on aggregated 13F filings for Q3 2024.